New applications of mRNA vaccine for treatment of experimental autoimmune encephalomyelitis

Researchers have designed an mRNA vaccine that delayed the onset and reduced the severity of multiple sclerosis-like disease in mice. The vaccine restores the body’s tolerance to its own proteins, suppressing the disease's immune overreactivity.

Corresponding author of this paper, Ugur Sahin is a German oncologist and entrepreneur. He is Professor of Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, and chairman of the board and CEO of Biopharmaceutical New Technologies (BioNTech) Corporation, which is one of the leading COVID-19 vaccine developers.



Reply

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2020 MolecularCloud